— Know what they know.
Not Investment Advice
Also trades as: 0H7R.L (LSE) · $vol 0M

ABEO NASDAQ

Abeona Therapeutics Inc.
1W: -3.3% 1M: -15.9% 3M: -28.6% YTD: -16.2% 1Y: -18.8% 3Y: +7.5% 5Y: -80.2%
$4.45
+0.14 (+3.25%)
 
Weekly Expected Move ±7.2%
$4 $4 $4 $5 $5
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $254.5M mcap · 36M float · 3.91% daily turnover · Short 52% of daily vol
Credit Risk of going bust: lower than 55% of companies Debt: 7.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99%), Abeona Therapeutics Inc. would be worth roughly what it owes.
Total debt $19.9M against a stock market value of $254.5M.
Distance to default 5.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $14.2M (short-term plus half of long-term), stock volatility 53.8%; Altman Z'' -9.24. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$254.5M
52W Range4-7.65
Volume663,227
Avg Volume1,410,605
Beta1.30
Dividend—
Analyst Ratings
6 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOVishwas Seshadri
Employees226
SectorHealthcare
IndustryBiotechnology
IPO Date1980-09-19
6555 Carnegie Avenue
Cleveland, OH 44103
US
646 813 4701
About Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Recent Insider Trades

NameTypeSharesPriceDate
Seshadri Vishwas S-Sale 19,608 $5.16 2026-09-29
Vazzano Joseph Walte S-Sale 9,191 $5.16 2026-09-29
O'Malley Brendan M. S-Sale 6,727 $5.16 2026-09-29
Vasanthavada Madhav S-Sale 4,902 $5.16 2026-09-29
Alvino Mark S-Sale 15,000 $5.86 2026-09-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms